Menu

Trump Nominates Alex Azar as Health and Human Services Secretary

The former chief of Eli Lilly USA is picked to replace Tom Price, who stepped down in September amid a controversy over the abuse of taxpayer-funded travel.

Nov 13, 2017
Catherine Offord

WIKIMEDIA, WWSGCONNECT

Update (January 25): The US Senate voted 55-43 to confirm former Eli Lilly executive Alex Azar as Health and Human Services Secretary on Wednesday (January 24). The vote was preceded by several critical speeches from Democrats who highlighted Azar’s oversight of Lilly’s drug price hikes while he was president of the companys US branch.

President Donald Trump has nominated Alex Azar, a former pharmaceutical executive and health care consultant, for the position of secretary of the US Health and Human Services (HHS) department. If confirmed by the Senate, Azar will be one of few HHS secretaries to have come from an industry the HHS regulates, rather than from a career primarily in government.

“Happy to announce, I am nominating Alex Azar to be the next HHS Secretary,” the President tweeted earlier today (November 13). “He will be a star for better healthcare and lower drug prices!”

The previous chief of HHS, Tom Price, stepped down from the position in September following reports that he had used unnecessary and costly private charter flights at taxpayers’ expense.

See “HHS Secretary Price Resigns After Criticism of Plane Travel

For most of the last decade, Azar worked for the US branch of the global pharmaceutical company Eli Lilly—he was the division’s president from 2012 to early 2017. Before that, the Yale Law School graduate worked as HHS deputy secretary for the George W. Bush administration.

If confirmed, Azar will be responsible for overseeing the running of the Affordable Care Act (ACA), Medicare, Medicaid, and the National Institutes of Health, with a budget of more than $1 trillion—more than any other single federal agency.

In a June interview with Bloomberg TV about his views on the ACA, or Obamacare, Azar said, “I’m not one to say many good things about Obamacare, but one of the nice things in it is [that] it does give a tremendous amount [of] authority to the secretary,” Bloomberg reports. “There are still changes that can be made to make it work a little better than it has been.” 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.

Thermo Fisher Scientific: Freezers for Biological Samples

Thermo Fisher Scientific: Freezers for Biological Samples

Fluctuations in temperature can reduce the efficacy, decompose, or shorten the shelf life of biologics. Therefore, it is important to store biologics at the right temperature using standardized protocols.